Polycystic ovary syndrome
Nature Reviews Disease Primers · 18.04.2024 · 10 (1)
DOI: 10.1038/s41572-024-00511-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nature Reviews Disease Primers, online erschienen am 18.04.2024. Verfasst von Elisabet Stener-Victorin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. elisabet.stener-victorin@ki.se. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Hyperandrogenism, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 510-mal zitiert (Crossref) und nennt 304 Literaturangaben.
Abstract (Originalsprache)
Despite affecting ~11-13% of women globally, polycystic ovary syndrome (PCOS) is a substantially understudied condition. PCOS, possibly extending to men's health, imposes a considerable health and economic burden worldwide. Diagnosis in adults follows the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, requiring two out of three criteria - clinical or biochemical hyperandrogenism, ovulatory dysfunction, and/or specific ovarian morphological characteristics or elevated anti-Müllerian hormone. However, diagnosing adolescents omits ovarian morphology and anti-Müllerian hormone considerations. PCOS, marked by insulin resistance and hyperandrogenism, strongly contributes to early-onset type 2 diabetes, with increased odds for cardiovascular diseases. Reproduction-related implications include irregular menstrual cycles, anovulatory infertility, heightened risks of pregnancy complications and endometrial cancer. Beyond physiological manifestations, PCOS is associated with anxiety, depression, eating disorders, psychosexual dysfunction and negative body image, collectively contributing to diminished health-related quality of life in patients. Despite its high prevalence persisting into menopause, diagnosing PCOS often involves extended timelines and multiple health-care visits. Treatment remains ad hoc owing to limited understanding of underlying mechanisms, highlighting the need for research delineating the aetiology and pathophysiology of the syndrome. Identifying factors contributing to PCOS will pave the way for personalized medicine approaches. Additionally, exploring novel biomarkers, refining diagnostic criteria and advancing treatment modalities will be crucial in enhancing the precision and efficacy of interventions that will positively impact the lives of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. elisabet.stener-victorin@ki.se.
- Monash Centre for Health Research and Implementation, Monash Health and Monash University, Melbourne, Victoria, Australia.
- Robinson Research Institute, Adelaide Medical School, Adelaide, South Australia, Australia.
- Department of Obstetrics and Gynecology, Penn State College of Medicine, Hershey, PA, USA.
- Department of Public Health Science, Penn State College of Medicine, Hershey, PA, USA.
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Zitieren
APA
Stener-Victorin, E., Teede, H., Norman, R. J., Legro, R., Goodarzi, M. O., Dokras, A., Laven, J., Hoeger, K., & Piltonen, T. T. (2024). Polycystic ovary syndrome. Nature Reviews Disease Primers, 10(1). https://doi.org/10.1038/s41572-024-00511-3
Vancouver
Stener-Victorin E, Teede H, Norman RJ, Legro R, Goodarzi MO, Dokras A, et al. Polycystic ovary syndrome. Nature Reviews Disease Primers. 2024;10(1). doi:10.1038/s41572-024-00511-3
BibTeX
@article{StenerVictorin2024,
author = {Stener-Victorin, Elisabet and Teede, Helena and Norman, Robert J and Legro, Richard and Goodarzi, Mark O and Dokras, Anuja and Laven, Joop and Hoeger, Kathleen and Piltonen, Terhi T},
title = {Polycystic ovary syndrome},
journal = {Nature Reviews Disease Primers},
year = {2024},
volume = {10},
number = {1},
doi = {10.1038/s41572-024-00511-3}
}
EUVIMED